A61P 37/04
Immunostimulants
A61P37/04 (Immunostimulants) appears on 12,710 US grants and 19,372 published applications in this corpus.
Search patents in A61P- Granted patents
- 12,710
- Published applications
- 19,372
- Assignees
- 5,859
- Inventors
- 29,510
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 4 | 0 |
| 1979 | 8 | 0 |
| 1980 | 16 | 0 |
| 1981 | 6 | 0 |
| 1982 | 12 | 0 |
| 1983 | 22 | 0 |
| 1984 | 19 | 0 |
| 1985 | 15 | 0 |
| 1986 | 13 | 0 |
| 1987 | 28 | 0 |
| 1988 | 18 | 0 |
| 1989 | 26 | 0 |
| 1990 | 24 | 0 |
| 1991 | 29 | 0 |
| 1992 | 22 | 0 |
| 1993 | 39 | 0 |
| 1994 | 28 | 0 |
| 1995 | 35 | 0 |
| 1996 | 64 | 0 |
| 1997 | 87 | 0 |
| 1998 | 157 | 0 |
| 1999 | 247 | 0 |
| 2000 | 230 | 0 |
| 2001 | 256 | 65 |
| 2002 | 248 | 353 |
| 2003 | 197 | 558 |
| 2004 | 127 | 599 |
| 2005 | 165 | 608 |
| 2006 | 221 | 605 |
| 2007 | 221 | 614 |
| 2008 | 304 | 769 |
| 2009 | 366 | 936 |
| 2010 | 494 | 1179 |
| 2011 | 602 | 1455 |
| 2012 | 693 | 1405 |
| 2013 | 736 | 906 |
| 2014 | 834 | 865 |
| 2015 | 725 | 865 |
| 2016 | 725 | 918 |
| 2017 | 704 | 898 |
| 2018 | 674 | 733 |
| 2019 | 670 | 810 |
| 2020 | 606 | 683 |
| 2021 | 492 | 614 |
| 2022 | 402 | 651 |
| 2023 | 340 | 595 |
| 2024 | 314 | 668 |
| 2025 | 282 | 550 |
| 2026 | 163 | 470 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Lipid nanoparticles comprising sterols and mRNA6 Oct 2026US 12,751,999 B2eTheRNA Immunitherapies NV
- Interferon gene stimulator composition comprising indolizine derivative as active ingredient29 Sep 2026US 12,746,252 B2Ajou University Industry-Academic Cooperation Foundation
- Immune adjuvant and vaccine composition including the same29 Sep 2026US 12,746,284 B2Republic of Korea (Animal and Plant Quarantine Agency)
- HERV-K (HML-2) Env analog fusion proteins for antigen specific immunotherapy and methods of use29 Sep 2026US 12,747,270 B2Twilight Bioscience, Inc.
- C-terminus modified human papilloma virus type 6 L1 protein and use thereof22 Sep 2026US 12,741,016 B2Chinese Academy of Medical Sciences
- Enhancer of number of tcr clones8 Oct 2026US 2026/0306562 A1Kabushiki Kaisha Yakult Honsha
- Antigen-specific physiologic dendritic cells for therapy8 Oct 2026US 2026/0306597 A1Emory University
- Timp3-derived teipp neoantigens and uses thereof8 Oct 2026US 2026/0306599 A1
- Sarcoma cancer vaccines and uses thereof8 Oct 2026US 2026/0306600 A1
- Lipid nanoparticles for the prevention of tuberculosis or other mycobacterial infections8 Oct 2026US 2026/0306603 A1Akagera Medicines, Inc.
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Antigen-adjuvant compositions and methods1,024US 8,790,658 B2Sanofi Pasteur Limited · 2014
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Immunostimulatory nucleic acid molecules472US 6,207,646 B1Coley Pharmaceutical Group, Inc. · 2001
- Immunostimulatory nucleic acid molecules461US 6,239,116 B1Coley Pharmaceutical Group, Inc. · 2001